Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure

Kidney International

Volumn 77, Issue 3, 2010, Pages 175-177

  Fishbane, Steven ^a   Miyawaki, Nobuyuki ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD PRESSURE MEASUREMENT; BLOOD VISCOSITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIURESIS; DOUBLE BLIND PROCEDURE; EXTERNAL VALIDITY; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 74549163582     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.455     Document Type: Note

References (10)

1. Szczech LA, Barnhart HX, Sapp S et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 2010; 77: 239-246.
2. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
3. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
4. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
5. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2: 1274-1282
6. Kilpatrick RD, Critchlow CW, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
7. Amgen announces top-line results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD patients with type-2 diabetes. Amgen Press Release. Yahoo! Finance (http://finance.yahoo.com/news/Amgen-Announces- TopLine-prnews-2902900089.html? x=0 &.v=1 accessed 9/10/09) 2009.
8. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189.
9. Vaisman N, Silverberg DS, Wexler D et al. Correction of anemia in patients with congestive heart failure increases resting energy expenditure. Clin Nutr 2004; 23: 355-361.
10. Mancini DM, Katz SD, Lang CC et al. Effect o f erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003; 107: 294-299.